Search

Displaying results 1761 - 1770 of 7452 in total
  1. Drug

    Chlorphenoxamine

    go.drugbank.com/drugs/DB09007
    ApprovedWithdrawn

    It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.

    Categories: Antihistamines for Topical Use, Antihistamines for Systemic Use
  2. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.

    Categories: Detoxifying Agents for Antineoplastic Treatment
  3. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

    Mixtures: NEPHROSTERIL FOR INTRAVENOUS INFUSION, AMINOSTERIL N-HEPA FOR INTRAVENOUS INFUSION 8%
  4. Drug

    Phenyltoloxamine

    go.drugbank.com/drugs/DB11160
    Approved

    Phenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine.

  5. Drug

    Subasumstat

    go.drugbank.com/drugs/DB16406
    Investigational

    Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)). … Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    May 2024 for the same indication. … [L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in

  7. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.

  8. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.

  9. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. … It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation.

  10. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    [A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression.